$PFSA

HRT FINANCIAL LP purchased $15K of PFSA

HRT FINANCIAL LP purchased 15,924 shares of Profusa, Inc. (PFSA) at an average of $0.96 ($0.95–$0.96) across 2 trades over 2026-08-03 to 2026-08-04.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 5, 2026, 5:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 5:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PFSA
Bullish
medium confidence
Mentioned
$PFSA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSABullishLow
01

Why it matters

The only new information is the disclosed purchase details (shares, price range, total value, and post-transaction holdings). It may slightly improve sentiment but does not change fundamentals.

02

Market read

Traders may note the 10% owner open-market buy, but the disclosed dollar amount is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The transaction value is small and spans two days; without additional context (e.g., other insiders buying/selling, liquidity, or subsequent filings), the signal may be statistically weak.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-05, covering purchases on 2026-08-03 to 2026-08-04

Background

The filing is a SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA), reported by HRT Financial LP as a 10% owner.

Company-level read

Ticker impact

$PFSABullishMedium confidence
Context

Profusa, Inc. (PFSA) disclosed an open-market purchase by 10% owner HRT Financial LP of 15,924 shares at about $0.9577.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless follow-on buying or other news emerges.

Evidence & confidence

Form 4 shows a modest dollar value transaction (~$15.25k) with no 10b5-1 plan, which can be read as supportive, but the size is small relative to typical market-moving thresholds and provides no new operating information.

Market effects

No clear sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

A 10% owner buy can be routine portfolio rebalancing or tax/position management, especially without a clear narrative or follow-on pattern.

Key entities

  • Profusa, Inc.

    Company subject of the Form 4 disclosure, ticker PFSA.

  • HRT Financial LP

    Reporter of the open-market purchase of PFSA shares.

Related articles

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.